{"id":578049,"date":"2026-08-01T00:51:22","date_gmt":"2026-08-01T00:51:22","guid":{"rendered":"https:\/\/www.newsbeep.com\/ie\/578049\/"},"modified":"2026-08-01T00:51:22","modified_gmt":"2026-08-01T00:51:22","slug":"reducing-the-risk-of-overt-hepatic-encephalopathy-recurrence","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ie\/578049\/","title":{"rendered":"Reducing the risk of overt hepatic encephalopathy recurrence"},"content":{"rendered":"

<\/p>\n

\"Reducing<\/p>\n

<\/a><\/p>\n

image:\u00a0<\/p>\n

A proposed algorithm for reducing the risk of OHE and treating HE recurrence is provided and based on hepatology society guidelines and a review of the literature. In all situations, correction of known precipitating factors and\/or secondary causes and avoidance of sedatives and narcotics are imperative. Lactulose is considered first-line therapy after an initial episode of HE. Lifestyle interventions, including nutritional supplementation and counseling, sleep hygiene, and mindfulness-based stress reduction therapy, may also be beneficial. Rifaximin plus lactulose therapy is recommended when additional HE episode(s) occur. Patients with recurrent or persistent HE should be evaluated for a shunt; SPSS embolization should be considered for those with an SPSS and MELD score < 11. In situations of recurrent or persistent HE refractory to pharmacologic therapy following TIPS implantation, evaluation for shunt reduction may be appropriate. Liver transplantation should be considered for patients with recurrent or persistent HE despite adequate treatment. Albumin dialysis for bridging to liver transplantation may be considered in patients with persistent, grade 3\u20134 HE. In addition, patient and caregiver education on HE symptoms and treatments, including the importance of long-term adherence, is advised for receptive individuals. Overall, the burden of HE is substantial and includes patient and caregiver QOL impairment and increased risk of patient hospitalization and mortality. Reducing the risk of HE recurrence is imperative given associated morbidity and mortality risks.<\/p>\n

view more\u00a0<\/a><\/p>\n

Credit: Nikolaos T. Pyrsopoulos<\/p>\n

Hepatic encephalopathy (HE) is a neurologic complication of advanced liver disease, causing impaired functioning, reduced quality of life (QOL), and increased hospitalisation and mortality. This review discusses HE burden, precipitating risk factors, and strategies to reduce overt HE (OHE) recurrence. Key precipitants include medications, constipation, dehydration, uncontrolled diabetes, electrolyte imbalances, GI bleeding, infection, and sarcopenia. Management involves education, nutritional support, pharmacotherapy, and nonpharmacologic interventions (shunt embolisation, transplantation). Guidelines recommend lactulose as secondary prophylaxis; rifaximin is added when further episodes occur. PEG and LOLA may have roles in certain patients. Investigational approaches include nitazoxanide, FMT, and AI\u2011based technologies.<\/p>\n

Introduction<\/p>\n

HE affects ~20% of US adults with cirrhosis (projected ~697,000 by 2030). It is classified by underlying disease (type A: acute liver failure; B: shunting; C: cirrhosis) and West Haven criteria (covert: minimal\/grade I; overt: grades II\u2013IV). OHE manifests as lethargy, disorientation, confusion, asterixis, and coma. Course may be episodic, recurrent (\u22652 episodes\/6 months), or persistent. Diagnosis is clinical, excluding other causes.<\/p>\n

Burden of HE<\/p>\n

HE profoundly impairs QOL\u2014affecting daily activities, work, independence\u2014and causes anxiety, social isolation, and sleep disturbances. Caregivers also experience significant psychosocial burden (depression\/anxiety in 28\u201339%). Employment is markedly reduced (13% vs. 81% without HE). Recurrent episodes may cause cumulative, irreversible cognitive impairment. Hospitalisation and readmission are common: 43.6% rehospitalised within one year; HE is the leading cause of 90\u2011day readmissions (~41%). HE\u2011related hospitalisation costs average $77,699 per episode; total annual US inpatient charges exceed $11 billion. Mortality is significantly higher with HE and increases with severity.<\/p>\n

Pathophysiology<\/p>\n

OHE arises from gut dysbiosis, hyperammonaemia, systemic inflammation, oxidative stress, altered neurotransmission, manganese deposition, zinc deficiency, and elevated bile acids\/lactate. Liver fails to clear toxins; portosystemic shunting redirects them systemically. Toxins cross the blood\u2013brain barrier, causing astrocyte swelling\/dysfunction, neuroinflammation, and neuronal damage. Systemic inflammation enhances ammonia neurotoxicity and increases barrier permeability, creating a positive feedback loop. Sarcopenia reduces muscle ammonia clearance and releases amino acids that generate ammonia.<\/p>\n

Precipitating and Associated Risk Factors<\/p>\n

Key precipitants include sedatives, opioids, statins, constipation, dehydration, uncontrolled diabetes, electrolyte imbalances, GI bleeding, infection, and sarcopenia. TIPS causes HE in 30\u201360%; risk factors include older age, higher MELD, prior HE, sarcopenia, renal impairment, diabetes, and stent diameter >10 mm. Nonadherence to treatment is common (only 35% adherent to lactulose) and strongly associated with recurrence (nonadherence increased OHE odds 3.3\u2011fold). Barriers include unpleasant taste, dose titration, and GI adverse effects.<\/p>\n

Reducing the Risk of HE Recurrence<\/p>\n

Education and Precipitant Correction:\u00a0Correcting precipitants is critical. A 15\u2011min educational intervention reduced HE\u2011related hospitalisations (HR 0.14). Education on medication, dosing, adverse events, and early signs improves adherence.<\/p>\n

Nutritional Support:\u00a0Daily intake of 35\u201340 kcal\/kg and 1.2\u20131.5 g\/kg protein is recommended; protein restriction should be avoided. Nutrition therapy reduced OHE episodes (13.3% vs. 48.0%) and hospitalisations. Zinc improves cognition but may not reduce recurrence. BCAA improves HE symptoms and may prevent recurrence. Sleep hygiene and mindfulness improve QOL; sedatives should be avoided.<\/p>\n

Pharmacotherapy:<\/p>\n

Lactulose\u00a0(titrated to 2\u20133 bowel movements\/day) is first\u2011line secondary prophylaxis. Recurrence reduced vs. no therapy (19.6% vs. 46.8%; 26.5% vs. 56.9%). Adverse effects: diarrhoea, distaste, bloating.<\/p>\n

Rifaximin 550 mg BID\u00a0is added when further episodes occur. Phase 3 trial: reduced breakthrough HE by 58% (HR 0.42) and HE\u2011related hospitalisations by 50% (HR 0.50). Meta\u2011analysis confirmed reduced recurrence (RR 0.49). Adverse effects: peripheral oedema, nausea, dizziness, fatigue, diarrhoea; rare C. difficile reported. Cost\u2011effective due to reduced healthcare utilisation. Emerging antimicrobial resistance concerns warrant further study.<\/p>\n

PEG\u00a0not studied as secondary prophylaxis but may be an alternative in acute HE or poor lactulose response.<\/p>\n

LOLA\u00a0reduced OHE recurrence in one RCT (12.3% vs. 27.8%; HR 0.39).<\/p>\n

Nonpharmacologic Interventions:<\/p>\n

SPSS embolisation\u00a0for recurrent\/persistent HE, MELD <11, and large shunts.<\/p>\n

TIPS reduction\u00a0for recurrent\/persistent HE refractory to pharmacotherapy.<\/p>\n

Liver transplantation\u00a0for recurrent\/persistent HE despite adequate treatment.<\/p>\n

Investigational Approaches:<\/p>\n

Nitazoxanide\u00a0reduced ammonia and prolonged time to recurrence vs. rifaximin.<\/p>\n

FMT\u00a0showed promising results (post\u2011hoc: recurrence 9.1% vs. 40.0% with placebo).<\/p>\n

AI, apps, and wearables\u00a0may facilitate adherence monitoring, stool tracking, and early detection.<\/p>\n

Barriers to Care<\/p>\n

Poor health literacy is associated with covert HE. Caregiver burden is substantial. Cost barriers and racial\/ethnic disparities exist in rifaximin prescribing and subspecialty referral. Treatment gaps (delays, interruptions) are common and associated with increased hospitalisations and costs.<\/p>\n

Conclusions and Future Directions<\/p>\n

A proposed algorithm emphasises precipitant correction, lifestyle interventions, and pharmacotherapy. Lactulose is first\u2011line; rifaximin added for breakthrough. Recurrent\/persistent HE should be evaluated for SPSS embolisation, TIPS reduction, or transplantation. Patient\/caregiver education is essential. Future priorities include predictive models (e.g., AMMON\u2011OHE), primary prevention, and large prospective international RCTs.<\/p>\n

\u00a0<\/p>\n

Full text<\/p>\n

https:\/\/www.xiahepublishing.com\/2310-8819\/JCTH-2025-00698<\/a><\/p>\n

\u00a0<\/p>\n

The study was recently published in the\u00a0Journal of Clinical and Translational Hepatology<\/a>.<\/p>\n

The Journal of Clinical and Translational Hepatology\u00a0(JCTH) is owned by the Second Affiliated Hospital of Chongqing Medical University and published by XIA & HE Publishing Inc. JCTH publishes high quality, peer reviewed studies in the translational and clinical human health sciences of liver diseases. JCTH has established high standards for publication of original research, which are characterized by a study\u2019s novelty, quality, and ethical conduct in the scientific process as well as in the communication of the research findings. Each issue includes articles by leading authorities on topics in hepatology that are germane to the most current challenges in the field. Special features include reports on the latest advances in drug development and technology that are relevant to liver diseases. Regular features of JCTH also include editorials, correspondences and invited commentaries on rapidly progressing areas in hepatology. All articles published by JCTH, both solicited and unsolicited, must pass our rigorous peer review process.<\/p>\n

Follow us on X:\u00a0@xiahepublishing<\/a><\/p>\n

Follow us on LinkedIn:\u00a0Xia & He Publishing Inc.<\/a><\/p>\n

Journal<\/p>\n

Journal of Clinical and Translational Hepatology<\/p>\n

Article Title<\/p>\n

Reducing the Risk of Overt Hepatic Encephalopathy Recurrence: A Narrative Review<\/p>\n

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.<\/p>\n